Bringing cell therapies from the lab to real-world application isn’t just about discovery—it’s about overcoming barriers to clinical success. Scaling these therapies requires optimizing delivery without sacrificing quality, efficacy, or consistency. At Likarda, we’re leading the way in hydrogel encapsulation technology, refining solutions for both in vitro and in vivo applications. By enhancing yield, reproducibility, and therapeutic impact, we help ensure that cell-based therapies can be delivered at scale—efficiently and effectively. Let’s explore how we can optimize your therapy. Drop a comment, DM, or email to [email protected] to discuss a FREE consultation with our team. #HealthcareInnovation #DrugDevelopment #FutureofMedicine
关于我们
Likarda is a biotech company developing enabling technologies to transform the way cell therapies are delivered and optimized. Our revolutionary method to coat cells with stealth hydrogels, called Core Shell Spherification? (CSS), protects cells from destruction, keeping them viable while maintaining them in the intended location within the body. Unlike our competitors, Likarda has developed a library of over 50 different hydrogel formulations that work with Core Shell Spherification?, resulting in the ability to uniquely tailor the coating molecules to the specific requirements of the therapeutic cells themselves. From durable and long-term coatings to degradable coatings that deliver cells over days, weeks, or months, we can create exclusive hydrogel formulations tailored for each therapeutic application. Likarda is the remarkable culmination of visionary leadership, science that is just as artistic as academic, and a compelling urge to do what’s right. As we move forward, we have well-defined, long-range goals with added opportunities for flexibility and growth.
- 网站
-
https://www.likarda.com
Likarda的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Kansas City,Missouri
- 类型
- 私人持股
- 创立
- 2012
- 领域
- Cell-based Therapies、Cell Therapy、Encapsulation、Microencapsulation、Cell-based Assay Development、Biotechnology和Hydrogels
地点
-
主要
10330 Hickman Mills Dr
US,Missouri,Kansas City
Likarda员工
动态
-
?? BIG NEWS! ?? What if a single dose of therapy could last months instead of days? That’s exactly what we’re working on at Likarda—and we’ve just received a major grant to bring this innovation to life! Many infectious diseases require frequent dosing, creating treatment challenges and poor adherence. Our Core-Shell Spherification? platform encapsulates therapeutic cells in a tunable hydrogel system, protecting them from immune clearance while enabling the controlled release of antibodies over an extended period of several months to a year. Why This Changes Everything: ?? Immune Protection – Shields cells for extended therapeutic impact. ?? Temperature-Stable Hydrogel – Built for durability and controlled release. ?? Expanding What’s Possible – Bringing scalable, long-term cell-based therapies closer to reality. ?? Read the full press release here: https://lnkd.in/g76dYYEm And this is just the beginning! ?? Hit ‘Follow’ to stay updated as Likarda continues to push the boundaries of what’s possible in biotech and global health. #HealthcareInnovation #CellTherapy #InfectiousDisease #DrugDelivery
-
-
?? Exciting News! ?? Likarda and our customer VitalTE are featured in the latest issue of European Pharmaceutical Manufacturer, discussing how hydrogels are transforming hormone delivery! ?? Our encapsulated hydrogel technology enables slow, controlled hormone release over the course of weeks, providing a more effective and patient-friendly injectable alternative to traditional pellet-based delivery. Preclinical studies indicate that our hydrogel microbeads achieve a similar release rate to pellet delivery, but with one key advantage—no need for an in-office insertion procedure! ?? Want to learn more? Check out the article and explore how Likarda is shaping the future of hormone delivery and drug release technologies. #DrugDelivery #Hydrogels #PharmaceuticalInnovation #HormoneTherapy #Biotech #Likarda #VitalTE #European Pharmaceutical Manufacturer
?? The latest issue of European Pharmaceutical Manufacturer is out NOW! ?? Read the full magazine here: https://lnkd.in/dJwHUiQj Sonia Schwantes, MBA, NewAge Industries, Inc. shares how the company is delivering value and sustainability. Stevanato Group delves into the one-stop shop for even the most challenging monoclonal antibodies. Aimee Hodge, PCI Pharma Services discusses PPQ pitfalls and how to avoid them. Deepa Pandey, Towards Packaging highlights the importance of flexible pouches in the pharma industry. Marcelo Cruz, Tjoapack explores the secondary innovations poised to revolutionise the patient centricity of prefilled syringes. Paul Hardman, Broughton looks into ways to reduce greenhouse gases in pharma. Danny Jones, ZwickRoell UK & Ireland highlights advances in parental drug delivery products and testing methods. Dr. Charles Virden, VitalTE LifeSciences Inc and Lisa Stehno-Bittel, Likarda discuss a new approach to HRT. Jeff Serle, Germfree demonstrates how multimodal and modular cleanrooms can satisfy all requirements. Beverley Wise, Webfleet, Bridgestone EMEA explores how fleet tech is reshaping the pharma supply chain. Stephen Cawley, Biocair shares the challenges and innovations in sustainability for the life sciences supply chain. Caroline Suard, Tower Cold Chain discusses the critical role of thermal packaging solutions in logistics. Kevin Lynch, Schneider Electric explains how the sector can leverage digital technologies to streamline the technology learning curve. Harvey Branton, eXmoor Pharma shares insights into early process development, exploring common misconceptions that could impact long-term manufacturing success for ATMP developers. Ray Baldwin, Watson-Marlow Fluid Technology Solutions explains how all single-use is not created equal and how you can tell the difference. Lars Petersen, FUJIFILM Diosynth Biotechnologies shares the latest updates on the ongoing expansion at the Hiller?d facilities. #packaging #biopharma #manufacturing #cleanrooms
-
-
Big solutions start with bold ideas! We’re excited to announce that Likarda has been selected to present at the BioTools Innovator East Coast Pitch Event tomorrow in Boston! Our Founder & President, Dr. Lisa Stehno-Bittel, will take the stage to showcase how Likarda's breakthrough cell therapy delivery technology is transforming the future of healthcare. This event brings together industry leaders, investors, and top innovators in life science tools and diagnostics—all focused on pushing the boundaries of biotech. We’re honored to be part of the conversation and can’t wait to share how our next-gen encapsulation platform is revolutionizing cell therapy. If you’re attending, let’s connect! Looking forward to an exciting day of innovation and collaboration. #BTIRoadTour2025 #CellTherapy #BiotechInnovation #StartupPitch
-
-
At Likarda, we don’t just talk about women in leadership—we live it. With a female President, CEO and CCO, we’re proof that when women lead, industries evolve, innovation accelerates, and meaningful change happens. As the world celebrates #InternationalWomensDay on March 8th, we honor the women making strides in science, medicine, and beyond—those who ask the tough questions, challenge the status quo, and push the boundaries of what’s possible. To every woman forging a path in biotech, healthcare, and STEM—keep leading, keep inspiring, and keep changing the world. We see you. We celebrate you. #WomenInSTEM #WomenInScience
-
-
What’s next for biopharma in 2025? In the latest installment of "Scrip Asks...", over 140 biopharma leaders—including Likarda CEO Stella K. Vnook—shared their insights on the biggest therapeutic advancements shaping the year ahead. From breakthroughs in oncology and immunology to game-changing innovations in cardiometabolism and neurology, the industry is set for a transformative year. ?? Read the full article, written by Eleanor Malone, here: https://bit.ly/3F281lk ?? What do you think will be the most impactful advancement in biopharma this year? Share your thoughts in the comments! #pharmainnovation #biotech Citeline
-
-
The pharmaceutical logistics industry faces a staggering challenge—an estimated $35 billion is lost annually due to temperature-controlled shipping failures. Equipment malfunctions, delays, and packaging issues compromise product integrity, leading to significant financial losses. This is where Likarda's hydrogel solutions can provide, well—a solution! Powered by our patented Core-Shell Spherification? technology, Likarda can create hydrogels that create physical insulators for sensitive pharmaceuticals for cryopreserved products and fresh shipping. One of our most transformative solutions is LiberaSphere?, designed to revolutionize drug transport. ?This innovative solution provides: - Cost-Effective Dry Ice Shipping: Eliminating the cost and complications of liquid nitrogen. - Reliable Drug Protection: Protecting cells against temperature shifts and damage. - Precision On-Demand Release: Easy removal with simple rinsing. ?LiberaSphere? is perfect for therapies requiring precise delivery, such as: - Biologic therapies needing global shipment with stable conditions - Temperature-sensitive medications needing robust encapsulation LiberaSphere? enhances safety and eliminates the risks of compromised shipments. This is not just a logistics solution; it’s a step toward better patient care and operational efficiency. Ready to transform your supply chain? Let’s connect and explore how LiberaSphere? can safeguard your therapies and reduce losses. #celltherapy #drugdevelopment #biotech
-
-
Heading to #DCATWeek2025? Let’s connect! Likarda CEO Stella K. Vnook will be in New York March 17-20, meeting with industry leaders to explore strategic partnerships in drug delivery and formulation. With customizable hydrogel technology, Likarda can help your?team enhance stability, optimize therapeutic efficiency, and streamline the logistics of your therapies to drive better outcomes. Let’s set up a time to meet—email?[email protected]. #DCATWeek #PharmaPartnerships? DCAT (Drug, Chemical & Associated Technologies Association)
-
-
Likarda's CEO, Stella K. Vnook, along with other thought leaders share their 2025 predictions for the cell and gene therapy industry.
Chief Executive Officer | Founder & President Biopharma Companies | Board Chair | Advisor | Mentor | Investor | Licensing | M&A | Strategy | Doctorate Degrees: Econ. Global PH &Pharmacy (Oncology) | MBA
What’s next for cell and gene therapy? Drug Discovery World experts weigh in on the breakthroughs, challenges, and game-changing innovations set to redefine the field. If you're in biotech, you won’t want to miss this! https://lnkd.in/eaxb4y_B Michael Kelly Natalia Elizalde Urdiain Josh Ludwig Lee Markwick Jason Jones Brian Burke Amanda Haupt Erik Digman Wiklund Drug Discovery World Likarda IB Communications #CellTherapy #GeneTherapy #BiotechInnovation #LifeSciences #FutureOfMedicine #Biopharma #RegenerativeMedicine #BiotechTrends #HealthcareInnovation #PrecisionMedicine #CDMO #BiotechInvesting #PharmaTech
-
In the ever-evolving world of pharmaceutical development, optimizing existing therapies is just as crucial as creating new ones. At Likarda, we believe enhancing your therapies can significantly improve patient outcomes and boost market success. ?? VitaCell?—one of our 50+ hydrogel solutions—helps elevate your formulations by: - Releasing therapeutic agents where and when needed, then dissolving naturally—no need for invasive follow-ups. - Focusing treatments on the target area, minimizing off-target effects and maximizing efficacy. - Simplifying the process for patients and providers, improving adherence and satisfaction. ?? VitaCell? is ideal for therapies that require precision and temporary action, including: - Localized Cancer Treatments: Directly delivering chemotherapy to tumor sites, boosting efficacy while sparing healthy tissue. - Controlled Release Therapies: Enhancing patient outcomes with an effective release mechanism, ensuring optimal results through natural degradation. VitaCell? isn’t just about new treatments—it’s about optimizing what you already offer. By improving precision, simplifying the process, and enhancing patient outcomes, VitaCell? unlocks the full potential of your therapies. ?? Ready to enhance your formulations? Let’s connect: likarda.com/contact-us #cancertreatment #cancertherapies #techforgood #biotech
-